<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0003613'>Antiphospholipid antibodies</z:hpo> (aPL Abs) are associated with <z:mp ids='MP_0005048'>thrombosis</z:mp> in patients with the <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> (APS) </plain></SENT>
<SENT sid="1" pm="."><plain>There is strong evidence that aPL Abs are pathogenic in vivo from studies in animal models </plain></SENT>
<SENT sid="2" pm="."><plain>Furthermore, there are now convincing data indicating that activation of complement is involved in those processes </plain></SENT>
<SENT sid="3" pm="."><plain>This report addresses current modalities of treatment, as well as recent findings with respect to molecular events triggered by aPL Abs on endothelial cells, platelets, monocytes and complement activation </plain></SENT>
<SENT sid="4" pm="."><plain>A separate section addresses recent findings with regard to the putative receptor(s) recognized by aPL Abs on target cells </plain></SENT>
<SENT sid="5" pm="."><plain>Based on experimental evidence using in vitro and in vivo models, new targeted therapies for treatment and/or prevention of <z:mp ids='MP_0005048'>thrombosis</z:mp> in APS are proposed and discussed </plain></SENT>
</text></document>